Latest Conference Articles

Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC).

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).

Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

The NJSHP's 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding.

Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status.

Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.

Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug interactions.

Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors.

Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.

Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.

Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management.

MRD testing transforms multiple myeloma treatment, guiding personalized strategies and improving patient outcomes through innovative testing methods.

Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the specific lipid-lowering therapy used.

Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond low-density lipoprotein cholesterol reduction.

Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk.

Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns.

Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings.

Explore how the gut microbiome influences cancer therapy responses, resistance mechanisms, and the potential of microbiota-focused strategies for improved outcomes.

GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic kidney disease, and cardiovascular events, with evidence suggesting that some of these benefits may occur independently of weight loss.

Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy.

Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as familial chylomicronemia syndrome.

Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute coronary syndrome.

Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer.